Kyverna Therapeutics is developing CAR T-cell therapies to induce sustained treatment-free remission in patients with B cell-driven autoimmune diseases. Their clinical-stage platform includes autologous and allogeneic therapies currently undergoing trials for conditions such as lupus nephritis and multiple sclerosis.
Funding
$60M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Patients with B cell-driven autoimmune diseases often face chronic conditions requiring continuous treatment to manage symptoms. Current therapies may not provide sustained remission, and patients can experience relapses or require ongoing medication, impacting their quality of life.
Solution
Kyverna Therapeutics is developing CAR T-cell therapies designed to induce sustained treatment-free remission in individuals with B cell-mediated autoimmune disorders. Their approach leverages the potential of engineered T cells to reset the immune system, offering a new therapeutic avenue. The company's clinical-stage platform includes both autologous and allogeneic CAR T-cell therapies, targeting a range of autoimmune diseases. By modifying a patient's own T cells (autologous) or using T cells from a donor (allogeneic) to target B cells, Kyverna aims to provide long-lasting relief from autoimmune conditions.
Target Audience
The primary target audience includes patients diagnosed with B cell-driven autoimmune diseases such as lupus nephritis, systemic sclerosis, myasthenia gravis, and multiple sclerosis, as well as the physicians treating these conditions.
Features
- Autologous CAR T-cell therapy (KYV-101) utilizing a patient's own engineered T cells.
- Allogeneic CAR T-cell therapy (KYV-201) using donor-derived engineered T cells.
- Targeted B cell depletion to address the underlying cause of autoimmune diseases.
- Clinical trials underway for lupus nephritis, systemic sclerosis, myasthenia gravis, and multiple sclerosis.
- Patient-centric approach with ongoing clinical trials at multiple locations.